Drug-Coated Beats Bare-Metal Stent for Safety, Efficacy

This article originally appeared here.
Share this content:
Drug-Coated Beats Bare-Metal Stent for Safety, Efficacy
Drug-Coated Beats Bare-Metal Stent for Safety, Efficacy

WEDNESDAY, Oct. 14, 2015 (HealthDay News) -- A drug-coated stent is superior to a bare-metal stent for patients at high risk for bleeding who undergo percutaneous coronary intervention (PCI), according to a study published online Oct. 14 in the New England Journal of Medicine to coincide with the Transcatheter Cardiovascular Therapeutics meeting, held from Oct. 11 to 15 in San Francisco.

Philip Urban, M.D., from Hôpital de la Tour in Switzerland, and colleagues conducted a randomized, double-blind trial to compare a drug-coated stent with a similar bare-metal stent in 2,466 patients with high bleeding risk undergoing PCI. Participants received one month of dual antiplatelet therapy.

The researchers found that the primary safety end point (composite of cardiac death, myocardial infarction, and stent thrombosis) occurred in 9.4 percent of the drug-coated-stent group and in 12.9 percent of the bare-metal-stent group (hazard ratio, 0.71). The primary efficacy end point (clinically driven target-lesion revascularization) occurred in 5.1 percent of the drug-coated-stent group and in 9.8 percent of the bare-metal-stent group (hazard ratio, 0.5).

"A polymer-free umirolimus-coated stent was superior to a bare-metal stent with respect to the primary safety and efficacy end points when used with a one-month course of dual antiplatelet therapy," the authors write.

The study was funded by Biosensors Europe.

Abstract
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Plan to Relax Coal-Fired Power Plant Rules Could Up Mortality

Plan to Relax Coal-Fired Power Plant Rules Could ...

EPA predicts between 470 and 1,400 premature deaths a year by 2030

FDA Extends EpiPen Expiration Dates to Tackle Shortage

FDA Extends EpiPen Expiration Dates to Tackle Shortage

Shortages due to factors such as supply disruptions and manufacturer issues

USPSTF Updates Guidance for Cervical Cancer Screening

USPSTF Updates Guidance for Cervical Cancer Screening

Cytology recommended every three years from age 21; different screening options from age 30 to 65

is free, fast, and customized just for you!




Already a member?

Sign In Now »